{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:13:08Z","timestamp":1791915188178,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31670816"],"award-info":[{"award-number":["31670816"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.prostaglandins.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T03:01:58Z","timestamp":1540177318000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Apolipoprotein A-IV: A potential therapeutic target for atherosclerosis"],"prefix":"10.1016","volume":"139","author":[{"given":"Jia","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12944-017-0625-0","article-title":"Hypertriglyceridemia and atherosclerosis","volume":"16","author":"Peng","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"8","key":"10.1016\/j.prostaglandins.2018.10.004_bib0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1194\/jlr.R052753","article-title":"Apolipoprotein A-IV: a protein intimately involved in metabolism","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.prostaglandins.2018.10.004_bib0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-2275(20)38785-X","article-title":"Plasma metabolism of apolipoprotein A-IV in humans","volume":"27","author":"Ghiselli","year":"1986","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1021\/bi00621a018","article-title":"Characterization of the apolipoproteins of rat plasma lipoproteins","volume":"16","author":"Swaney","year":"1977","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.prostaglandins.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1161\/ATVBAHA.113.301948","article-title":"Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion","volume":"33","author":"VerHague","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2018.10.004_bib0030","doi-asserted-by":"crossref","first-page":"R1382","DOI":"10.1152\/ajpregu.2001.280.5.R1382","article-title":"Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus","volume":"280","author":"Liu","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"G628","DOI":"10.1152\/ajpgi.00225.2011","article-title":"Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function","volume":"302","author":"Kohan","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2018.10.004_bib0040","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1074\/jbc.M502501200","article-title":"Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size","volume":"281","author":"Lu","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.prostaglandins.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0022-2275(20)37153-4","article-title":"Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice","volume":"38","author":"Weinstock","year":"1997","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.prostaglandins.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"G519","DOI":"10.1152\/ajpgi.00189.2007","article-title":"Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion","volume":"293","author":"Black","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"24","key":"10.1016\/j.prostaglandins.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1073\/pnas.1201433109","article-title":"Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.prostaglandins.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"G680","DOI":"10.1152\/ajpgi.00075.2015","article-title":"The role of apolipoprotein A-IV in regulating glucagon-like peptide-1 secretion","volume":"309","author":"Wang","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1074\/jbc.M113.511766","article-title":"Apolipoprotein A-IV reduces hepatic gluconeogenesis through nuclear receptor NR1D1","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0070","first-page":"99","article-title":"Apolipoprotein A-IV in diabetes mellitus","volume":"21","author":"Verges","year":"1995","journal-title":"Diabetes Metab."},{"issue":"8","key":"10.1016\/j.prostaglandins.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1194\/jlr.M400130-JLR200","article-title":"The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease","volume":"45","author":"Wong","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.prostaglandins.2018.10.004_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2016.04.019","article-title":"Plaque stabilizing effects of apolipoprotein A-IV","volume":"251","author":"Geronimo","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.prostaglandins.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOL.0000000000000074","article-title":"High-density lipoprotein metabolism, composition, function, and deficiency","volume":"25","author":"Schaefer","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2018.10.004_bib0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.14348\/molcells.2015.0052","article-title":"Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity","volume":"38","author":"Yoo","year":"2015","journal-title":"Molecules and cells"},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.atherosclerosis.2012.07.029","article-title":"HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells","volume":"225","author":"Wang","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.prostaglandins.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/CIRCRESAHA.115.306246","article-title":"Microdomains, Inflammation, and Atherosclerosis","volume":"118","author":"Sorci-Thomas","year":"2016","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0105","doi-asserted-by":"crossref","first-page":"C95","DOI":"10.1152\/ajpcell.00388.2005","article-title":"Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competent, undifferentiated cells by modulating intracellular glutathione redox balance","volume":"290","author":"Spaulding","year":"2006","journal-title":"Am. J. Physiol., Cell Physiol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.ATV.21.6.1023","article-title":"Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice","volume":"21","author":"Ostos","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.25011\/cim.v36i4.19954","article-title":"Decreased plasma apolipoprotein A-IV levels in patients with acute coronary syndrome","volume":"36","author":"Li","year":"2013","journal-title":"Clin. Invest. Med."},{"issue":"3","key":"10.1016\/j.prostaglandins.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0735-1097(00)00775-0","article-title":"Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease","volume":"36","author":"Kronenberg","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2018.10.004_bib0125","first-page":"275","article-title":"The relationship between plasma apolipoprotein A-IV levels and coronary heart disease","volume":"114","author":"Manpuya","year":"2001","journal-title":"Chin. Med. J."},{"issue":"23","key":"10.1016\/j.prostaglandins.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","article-title":"RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo","volume":"55","author":"Bailey","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","article-title":"Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease","volume":"18","author":"Nicholls","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"16","key":"10.1016\/j.prostaglandins.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/hmg\/ddw211","article-title":"A genome-wide association meta-analysis on apolipoprotein A-IV concentrations","volume":"25","author":"Lamina","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"24","key":"10.1016\/j.prostaglandins.2018.10.004_bib0145","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/11.24.3039","article-title":"Relative contribution of variation within the APOC3\/A4\/A5 gene cluster in determining plasma triglycerides","volume":"11","author":"Talmud","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/FPC.0b013e32831e030e","article-title":"Pharmacogenetic association of the APOA1\/C3\/A4\/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study","volume":"19","author":"Liu","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"11","key":"10.1016\/j.prostaglandins.2018.10.004_bib0155","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1194\/jlr.M600303-JLR200","article-title":"Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha","volume":"47","author":"Hanniman","year":"2006","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1038\/s41598-017-07213-9","article-title":"Evaluating the causal relation of apoA-IV with disease-related traits - a bidirectional two-sample mendelian randomization study","volume":"7","author":"Mack","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.prostaglandins.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1194\/jlr.M019992","article-title":"ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins","volume":"53","author":"Weinberg","year":"2012","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.prostaglandins.2018.10.004_bib0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2010.00809.x","article-title":"Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients","volume":"14","author":"Omori","year":"2010","journal-title":"Ther. Apher. Dial."},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCOUTCOMES.113.000675","article-title":"High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease","volume":"7","author":"Akinkuolie","year":"2014","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-016-0428-z","article-title":"Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases","volume":"15","author":"Girona","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"23","key":"10.1016\/j.prostaglandins.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10118","key":"10.1016\/j.prostaglandins.2018.10.004_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.prostaglandins.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.prostaglandins.2018.10.004_bib0200","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/01.ATV.0000119353.03690.22","article-title":"Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide","volume":"24","author":"Recalde","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1172\/JCI200421233","article-title":"Apolipoprotein A-IV inhibits experimental colitis","volume":"114","author":"Vowinkel","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbrc.2017.04.058","article-title":"Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes","volume":"487","author":"Zhang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.prostaglandins.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.3150","article-title":"Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis","volume":"19","author":"Murphy","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.prostaglandins.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI5487","article-title":"\u03b23-integrin\u2013deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival","volume":"103","author":"Hodivala-Dilke","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prostaglandins.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1038\/s41467-018-05806-0","article-title":"Apolipoprotein A-IV binds alphaIIbbeta3 integrin and inhibits thrombosis","volume":"9","author":"Xu","year":"2018","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.prostaglandins.2018.10.004_bib0230","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2017.08.053","article-title":"Glycated Apolipoprotein A-IV Induces Atherogenesis in Patients With CAD in Type 2 Diabetes","volume":"70","author":"Dai","year":"2017","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882318301072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882318301072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:00:11Z","timestamp":1761098411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882318301072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":46,"alternative-id":["S1098882318301072"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2018.10.004","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein A-IV: A potential therapeutic target for atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}